Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS Buying Padlock For Up To $600 Million

This article was originally published in Start Up

Executive Summary

Two years, $18 million and a big pharma buyout for up to $600 million? That's a great return for investors in Padlock Therapeutics, a biotech firm that raised a single venture capital round in late 2014 to develop novel treatments for autoimmune diseases before Bristol-Myers Squibb agreed to buy the company.

Advertisement

Related Content

Finance Watch: J&J Notes JLabs Incubators' Success Stories To Date
Venture Funding Deals: LAM Nabs $58m Series C One Year After $40m Round

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092831

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel